Editorial PD_R1 1102.docx (50.82 kB)
What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs?
journal contribution
posted on 2023-08-30, 16:07 authored by Uros Milenkovic, Marcus M. Ilg, Selim Cellek, Maarten AlbersenFinding novel medical treatment for Peyronie’s disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Inhibiting one cog in this large machinery usually leads to activation of compensatory mechanisms.Expert opinion: Novel strategies in drug discovery such as phenotypical drug screening and gene expression profiling technologies could provide a solution for this impasse.
History
Refereed
- Yes
Volume
24Issue number
1Page range
1-4Publication title
Expert Opinion on Emerging DrugsISSN
1472-8214External DOI
Publisher
Taylor & FrancisFile version
- Accepted version
Language
- eng
Official URL
Legacy posted date
2019-03-19Legacy creation date
2019-03-19Legacy Faculty/School/Department
Faculty of Health, Education, Medicine & Social CareUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC